Minerva Neurosciences (NERV) Hits New 52-Week Low at $5.51
Minerva Neurosciences Inc (NASDAQ:NERV)’s share price hit a new 52-week low during trading on Monday . The company traded as low as $5.51 and last traded at $6.69, with a volume of 9250 shares trading hands. The stock had previously closed at $6.91.
A number of equities analysts have recently commented on NERV shares. ValuEngine downgraded shares of Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 15th. BidaskClub downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 17th. Finally, Zacks Investment Research downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 17th.
Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.06). On average, equities research analysts predict that Minerva Neurosciences Inc will post -1.62 earnings per share for the current year.
WARNING: “Minerva Neurosciences (NERV) Hits New 52-Week Low at $5.51” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/minerva-neurosciences-nerv-hits-new-52-week-low-at-5-51/3011023.html.
About Minerva Neurosciences (NASDAQ:NERV)
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.